The STEP 4 Data: What Stopping Actually Looks Like
The clearest picture of what happens when you stop GLP-1 medications comes from the STEP 4 trial, published in JAMA in 2021. Researchers took patients who had been on semaglutide for 20 weeks and achieved significant weight loss, then randomized them: half continued on semaglutide, half switched to placebo.
The results were stark. Over the following 48 weeks:
- The group that continued semaglutide lost an additional 7.9% of body weight
- The group that switched to placebo regained 6.9% of body weight on average — nearly all the weight they had lost during the first 20 weeks
- By the end of the study, the two groups differed by approximately 14.8 percentage points of body weight
A follow-up of STEP 1 patients who discontinued semaglutide at week 68 showed that within one year off the drug, participants had regained approximately two-thirds of the weight they had lost.
| Timepoint | Continued GLP-1 | Discontinued GLP-1 |
|---|---|---|
| At discontinuation | — | ~15% weight loss achieved |
| 6 months after stopping | Still losing | ~8–10% weight regained |
| 12 months after stopping | Continued maintenance | ~11–12% regained (two-thirds of loss) |
| Cardiometabolic markers | Continued improvement | Return toward baseline |
Obesity is now understood as a chronic disease with a strong biological component. GLP-1 medications work by suppressing appetite hormones and slowing gastric emptying. When you stop the medication, these effects cease — appetite signals return, the hormonal drive to regain weight resumes, and without the drug's pharmacological effect, most patients drift back toward their pre-treatment set point. This is not a failure of willpower. It is the expected physiological response to stopping a medication that was actively overriding a biological process.
Is This Different From Other Medications?
The weight regain pattern with GLP-1 medications is functionally similar to what happens with antihypertensives, statins, or antidepressants when patients stop taking them. The underlying condition — elevated blood pressure, high cholesterol, depression, or obesity — doesn't resolve because a medication was taken for a period of time. The medication manages it.
This framing shift — from "a treatment course" to "a chronic disease management strategy" — is one of the most important conceptual changes in obesity medicine in the past decade. It has implications for how patients and providers think about duration, cost, and long-term commitment.
Who Can Stop Successfully?
While the average outcome involves significant weight regain, the population is not uniform. Some patients do better after discontinuation than others. Factors associated with better outcomes after stopping include:
- Significant behavioral change during treatment: Patients who used the reduced-appetite period to build lasting habits (consistent exercise, protein-first eating patterns, improved sleep) tend to retain more of their loss
- Longer treatment duration: Some evidence suggests that patients on GLP-1s for 2+ years before discontinuing have somewhat better weight maintenance than those who stop earlier
- Lower starting BMI: Patients who were closer to a healthy BMI target tend to regain less, possibly because they have less distance to drift back
- Hormonal and surgical context: Patients who also underwent lifestyle changes, bariatric surgery, or hormone optimization may have additional metabolic support
But these are averages from small subgroups. The robust finding — that most patients regain significant weight after discontinuation — holds across the literature.
Tapering vs. Cold Stop
There is no established clinical protocol for tapering GLP-1 medications before stopping, in the same way there is for steroids or some antidepressants. The medications have long half-lives (semaglutide's half-life is approximately 7 days, tirzepatide's approximately 5 days), which means they clear slowly from the body naturally.
Some prescribers recommend stepping down the dose before fully stopping — for example, moving from the 2.4mg semaglutide dose to 1mg before discontinuing — to reduce the abruptness of the return of appetite. The evidence base for this specific approach is limited, but there is clinical logic to it.
More important than the tapering method is having a plan for what comes after: nutrition strategy, exercise routine, and regular monitoring with your provider.
Reasons Patients Stop GLP-1 Medications
Understanding why patients discontinue helps contextualize the discussion:
- Cost: The most common reason — insurance coverage lapses, savings programs expire, or out-of-pocket costs become unsustainable
- Persistent side effects: Nausea, constipation, or other GI effects that don't resolve even at maintenance doses
- Reaching a goal weight: Patients who achieve their target and feel ready to maintain independently
- Pregnancy planning: GLP-1 medications are not recommended during pregnancy; patients planning to conceive are typically counseled to stop 2 months before trying
- Surgery: Patients undergoing elective surgery are often asked to stop due to effects on gastric emptying and anesthesia risk
- Insurance or formulary changes: Coverage decisions that happen independent of clinical outcomes
Planning for Long-Term Use
If you and your provider determine that long-term use is appropriate and financially sustainable, the evidence suggests this is medically reasonable. The SURMOUNT-5 data on tirzepatide and the SELECT trial data on semaglutide show continued benefits — including cardiovascular risk reduction — with long-term use.
- What is the plan if my insurance stops covering this?
- How will we monitor my health markers on an ongoing basis?
- At what point, if any, do you expect we might trial discontinuation?
- If I do stop, what should the plan look like for the first 6 months?
- Are there lower doses I might maintain on long-term that cost less?
Maintenance Dosing: An Emerging Strategy
Some providers and researchers are exploring whether patients who have reached their goal weight can transition to lower maintenance doses rather than stopping completely. The idea: use the lowest effective dose to prevent regain, rather than the higher doses needed for active weight loss.
This is not yet a formally studied or recommended protocol for the branded medications, but it mirrors how Ozempic (2mg for diabetes) and Wegovy (2.4mg for weight loss) already differ by dose. The possibility that some patients might maintain on 0.5mg or 1mg semaglutide long-term — at significantly lower cost — is being discussed in the clinical literature.
Lilly's SURMOUNT program included data suggesting maintenance benefits at lower tirzepatide doses as well. As the long-term evidence base matures, maintenance dosing strategies will likely become more formalized.
Most patients regain a significant portion of lost weight within 12 months of stopping GLP-1 medications. This reflects the biology of obesity, not a personal failure. The decision to start, continue, or stop should be made with your provider based on your specific health goals, cost situation, and long-term plan — not on assumptions that the medication is a short-term fix. For most patients, the evidence currently supports treating GLP-1 medications as long-term therapy for a chronic condition.